Top Page
HCW Biologics
(NASDAQ:HCWB)
HCW Biologics (HCWB) vs. SPDR S&P 500 ETF (SPY)
HCW Biologics Business Overview & Revenue Model
HCW Biologics Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.57M | 2.84M | 6.72M | 0.00 | 4.10M |
| Gross Profit | 959.40K | 560.36K | 2.59M | -543.60K | 4.10M |
| EBITDA | -27.68M | -23.58M | -14.18M | -12.82M | -5.25M |
| Net Income | -30.02M | -24.99M | -14.72M | -12.36M | -5.78M |
Balance Sheet | |||||
| Total Assets | 30.24M | 28.51M | 46.81M | 53.51M | 15.40M |
| Cash, Cash Equivalents and Short-Term Investments | 4.67M | 3.60M | 32.06M | 36.71M | 8.46M |
| Total Debt | 13.69M | 6.30M | 6.41M | 0.00 | 567.31K |
| Total Liabilities | 37.01M | 15.05M | 9.38M | 2.32M | 1.00M |
| Stockholders Equity | -6.77M | 13.46M | 37.43M | 51.19M | 14.40M |
Cash Flow | |||||
| Free Cash Flow | -14.49M | -28.72M | -20.66M | -11.02M | -10.62M |
| Operating Cash Flow | -14.23M | -22.51M | -10.39M | -10.98M | -10.43M |
| Investing Cash Flow | -261.62K | 3.80M | 14.71M | -35.02M | -186.68K |
| Financing Cash Flow | 15.57M | -14.53K | 6.27M | 49.27M | 11.72M |
HCW Biologics Technical Analysis
HCW Biologics Risk Analysis
HCW Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ¥354.29B | 10.98 | -2.99% | 2.48% | 11.72% | -10.32% | |
49 Neutral | $9.17M | ― | -451.34% | ― | ― | -57.84% | |
47 Neutral | $10.64M | ― | -9999.00% | ― | -63.20% | 15.71% | |
42 Neutral | $14.17M | ― | -362.79% | ― | 32.45% | 39.31% | |
40 Underperform | $9.74M | ― | -59.80% | ― | 157.63% | 40.52% | |
34 Underperform | $8.20M | ― | -126.03% | ― | -100.00% | -27.44% |
HCW Biologics Corporate Events
On May 29, 2025, WY Biotech Co., Ltd. completed its due diligence on HCW Biologics‘ technical report and chose to proceed with their exclusive license agreement, obligating WY Biotech to pay a $7.0 million upfront license fee. To accommodate WY Biotech’s arrangements with its CDMO and investors, the payment deadline was extended to September 30, 2025, potentially impacting HCW Biologics’ financial operations and stakeholder interests.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On May 13, 2025, HCW Biologics Inc. entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd., which included pre-funded warrants for shares of the company’s common stock. By June 18, 2025, Armistice had fully exercised these warrants, purchasing a total of 513,140 shares, indicating a completed transaction with no remaining warrants outstanding.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On June 26, 2025, HCW Biologics Inc. announced it regained compliance with all Nasdaq Capital Market listing requirements, following a formal notice from Nasdaq confirming compliance with the Equity Rule. The company had previously addressed compliance issues related to bid price, public float, and market value of publicly held shares by May 13, 2025. HCW Biologics will remain under a Panel Monitor for a year, ensuring continued adherence to Nasdaq’s standards.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On June 17, 2025, HCW Biologics Inc. accepted the resignation of Gary M. Winer from its Board of Directors, with no immediate plans to fill his position. The resignation was not due to any disagreements with the company. During the same Annual Meeting, stockholders elected new Class I directors and ratified Crowe LLP as the independent accounting firm for the fiscal year ending December 31, 2025. Despite technical difficulties during the virtual meeting, a quorum was achieved, and the meeting was validly held. Broadridge Financial Solutions, the service provider, will send a letter to stockholders with a replay link and a platform for submitting questions.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On May 13, 2025, HCW Biologics Inc. entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd., granting pre-funded warrants for up to 513,140 shares of common stock. Armistice exercised these warrants on several occasions in May and June 2025, purchasing a total of 459,140 shares, with the potential to purchase an additional 54,000 shares, indicating strong investor interest and potential capital infusion for HCW Biologics.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
In May 2025, HCW Biologics Inc. successfully met Nasdaq’s continued listing requirements by evidencing compliance with the Bid Price Rule and MVPHS Rule, following a series of financial maneuvers including a $6.6 million Senior Note Conversion and a $5.0 million equity financing. Additionally, the company completed its obligations under the WY Agreement, securing a $7.0 million upfront license fee, and suspended the Wugen License Agreement for 12 months, enhancing its financial standing and operational flexibility.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On June 4, 2025, HCW Biologics announced that WY Biotech completed its due diligence on the technology transfer report for HCW11-006, confirming its commitment to develop and commercialize the molecule under an amended license agreement. This agreement, which includes a $7.0 million upfront licensing fee, positions HCW Biologics to receive additional milestone payments and royalties, while allowing them to opt-in for commercialization rights in certain territories after Phase 1 trials, impacting their financial and strategic positioning in the biopharmaceutical industry.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
HCW Biologics Inc. entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. on May 13, 2025, which included pre-funded warrants for purchasing up to 513,140 shares of common stock. By May 29, 2025, Armistice had exercised warrants to acquire a total of 374,140 shares, leaving 139,000 shares still available for purchase, indicating a significant engagement with Armistice that could impact the company’s financial operations and market positioning.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On May 13, 2025, HCW Biologics Inc. entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd., granting pre-funded warrants for up to 513,140 shares of common stock. Following this, on May 15 and May 22, 2025, Armistice exercised some of these warrants, resulting in the issuance of 177,140 and 126,000 shares respectively, with 210,000 warrants remaining.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On May 13, 2025, HCW Biologics entered into a Securities Purchase Agreement with Armistice Capital Master Fund, granting pre-funded warrants to purchase shares of common stock. Subsequently, Armistice exercised some of these warrants, resulting in the issuance of 177,140 shares. Additionally, the company converted $270,000 of unsecured convertible promissory notes into common stock, with shares issued to key executives and board members, reflecting strategic financial maneuvers to strengthen its capital structure.
The most recent analyst rating on (HCWB) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On May 13, 2025, HCW Biologics Inc. announced the pricing of a $5.0 million follow-on public offering, involving the sale of 671,140 units consisting of shares, pre-funded warrants, and common stock warrants. The offering, which closed on May 15, 2025, aims to support the company’s preclinical and clinical development, business development, and other corporate purposes. Additionally, the company negotiated to amend existing warrants, reducing their exercise price, which could impact stakeholder value and market positioning.
The most recent analyst rating on (HCWB) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.